Company logo

PODD - Insulet Corporation

NASDAQ -> Healthcare -> Medical Devices
Acton, United States
Type: Equity

PODD price evolution
PODD
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Current assets
Cash $109.1 $821 $751.2 $704.2
Short term investments
Net receivables $375.6 $348.6 $320.5 $359.7
Inventory $444.9 $430.9 $430.6 $402.6
Total current assets $1860.9 $1748.8 $1618.4 $1582.9
Long term investments
Property, plant & equipment $702.9 $677.9 $667.7 $664.9
Goodwill & intangible assets $150.2 $150.2 $150.4
Total noncurrent assets $1132.8 $1005.6 $1005.3
Total investments
Total assets $3025.4 $2881.6 $2624 $2588.2
Current liabilities
Accounts payable $40.3 $76.8 $75.9 $19.2
Deferred revenue
Short long term debt $37.9 $38.9 $49.4
Total current liabilities $506.2 $486 $432.4 $451.2
Long term debt $1356.3 $1359.9 $1362.6 $1366.4
Total noncurrent liabilities $1397.2 $1400.9 $1404.3
Total debt $1397.8 $1401.5 $1415.8
Total liabilities $1907.4 $1883.2 $1833.3 $1855.5
Shareholders' equity
Retained earnings -$60.4 -$137.9 -$326.5 -$378
Other shareholder equity $7.5 -$4.4 -$0.5 $8
Total shareholder equity $998.4 $790.7 $732.7
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $704.2 $136.1 $791.6 $907.2
Short term investments $40.4
Net receivables $359.7 $205.6 $161 $83.8
Inventory $402.6 $346.8 $303.2 $154.3
Total current assets $1582.9 $1314 $1329.8 $1248.7
Long term investments
Property, plant & equipment $664.9 $625.9 $536.5 $478.7
Goodwill & intangible assets $150.4 $127.2 $76.4 $68.5
Total noncurrent assets $1005.3 $937.1 $719 $624.2
Total investments $40.4
Total assets $2588.2 $2251.1 $2048.8 $1872.9
Current liabilities
Accounts payable $19.2 $30.8 $198.7 $54.1
Deferred revenue
Short long term debt $49.4 $27.5 $25.1 $15.6
Total current liabilities $451.2 $364.7 $228.8 $207.8
Long term debt $1366.4 $1374.3 $1248.8 $1043.7
Total noncurrent liabilities $1404.3 $1410 $1263.7 $1061.5
Total debt $1415.8 $1401.8 $1273.9 $1059.3
Total liabilities $1855.5 $1774.7 $1492.5 $1269.3
Shareholders' equity
Retained earnings -$378 -$584.3 -$649.5 -$666.3
Other shareholder equity $8 -$17 -$2.2 $5.5
Total shareholder equity $732.7 $476.4 $556.3 $603.6
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Revenue
Total revenue $543.9 $488.5 $441.7 $509.8
Cost of revenue $157.6 $134.9 $148.6
Gross Profit $377.1 $330.9 $306.8 $361.2
Operating activities
Research & development $53.9 $50.2 $42
Selling, general & administrative $222.4 $199.7 $212.8
Total operating expenses $289 $276.3 $249.9 $254.8
Operating income $54.6 $56.9 $106.4
Income from continuing operations
EBIT $62.1 $65.6 $114.5
Income tax expense $5.4 -$137.5 $3.4 $4.5
Interest expense -$1.8 $11 $10.7 $6.7
Net income
Net income $77.5 $188.6 $51.5 $103.3
Income (for common shares) $188.6 $51.5 $103.3
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $1697.1 $1305.3 $1098.8 $904.4
Cost of revenue $537.2 $499.7 $346.7 $322.1
Gross Profit $1159.9 $805.6 $752.1 $582.3
Operating activities
Research & development $205 $180.2 $160.1 $146.8
Selling, general & administrative $734.9 $587.8 $466 $384
Total operating expenses $939.9 $768 $626.1 $530.8
Operating income $220 $37.6 $126 $51.5
Income from continuing operations
EBIT $250.8 $36.5 $81.7 $54.8
Income tax expense $8.3 $5.2 $3.7 $2.9
Interest expense $36.2 $26.7 $61.2 $45.1
Net income
Net income $206.3 $4.6 $16.8 $6.8
Income (for common shares) $206.3 $4.6 $16.8 $6.8
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Net income $188.6 $51.5 $103.3
Operating activities
Depreciation $19.2 $18.8 $18.8
Business acquisitions & disposals
Stock-based compensation $17 $14.2 $12.6
Total cash flows from operations $96.5 $87.6 $45.2
Investing activities
Capital expenditures -$24.9 -$24 -$56.7
Investments
Total cash flows from investing -$78.2 -$24.9 -$24 -$31.6
Financing activities
Dividends paid
Sale and purchase of stock $7.1 $5.8 $9
Net borrowings -$6.9 -$14.9 -$7
Total cash flows from financing -$7.2 -$0.9 -$14.1 $2.2
Effect of exchange rate $1.2 -$0.9 -$2.5 $3
Change in cash and equivalents $198.4 $69.8 $47 $18.8
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income $206.3 $4.6 $16.8 $6.8
Operating activities
Depreciation $72.8 $63.2 $57.4 $55.4
Business acquisitions & disposals -$3 -$26
Stock-based compensation $48.3 $40.9 $34.4 $35.9
Total cash flows from operations $145.7 $119 -$68.1 $84
Investing activities
Capital expenditures -$109.2 -$135.8 -$111.9 -$129
Investments -$7.2 -$7.8 $40 $180.5
Total cash flows from investing -$119.4 -$191.1 -$82.7 $14
Financing activities
Dividends paid
Sale and purchase of stock $26.9 $16.3 $23.5 $509.2
Net borrowings -$27.3 -$39.8 $45.4 $128.3
Total cash flows from financing -$13.6 -$40.3 $40.7 $605.5
Effect of exchange rate $1.8 -$4.3 -$5.5 $4.8
Change in cash and equivalents $14.5 -$116.7 -$115.6 $708.3
News
Insulet Earnings: What To Look For From PODD
StockStory · via Yahoo Finance 19 Feb 2025
PODD Stock Gains From the Launch of Omnipod 5 in Five Countries in EU
Zacks · via Yahoo Finance 14 Jan 2025
What Does Insulet Corporation's (NASDAQ:PODD) Share Price Indicate?
Simply Wall St. · via Yahoo Finance 7 Jan 2025
Is Insulet Corporation (NASDAQ:PODD) The Top Stock With Improving Technical...
Insider Monkey · via Yahoo Finance 11 Oct 2024
Fidelity Growth Strategies Fund Trimmed Insulet Corporation (PODD) to Manage the...
Insider Monkey · via Yahoo Finance 4 Oct 2024
Insulet Corporation (PODD): This Diabetes Stock Is A Good Addition To Your...
Insider Monkey · via Yahoo Finance 24 Aug 2024
Insulet (PODD) Q1 Earnings Top, 2024 Revenue View Raised
Zacks via Yahoo Finance 15 May 2024
American Politicians are Selling These 10 Stocks
Insider Monkey via Yahoo Finance 28 Apr 2024
Insulet (PODD) Awaits Q1 Earnings Release: Here's What to Expect
Zacks via Yahoo Finance 24 Apr 2024
Can Higher Visits Soften Cost Blow for Teladoc (TDOC) in Q1?
Zacks via Yahoo Finance 23 Apr 2024
Fundamentals
Market cap $19.84B
Enterprise value N/A
Shares outstanding 70.14M
Revenue $1.98B
EBITDA N/A
EBIT N/A
Net Income $420.90M
Revenue Q/Q 25.70%
Revenue Y/Y 27.42%
P/E ratio 47.13
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio 10.00
P/B ratio N/A
Book/Share N/A
Cash/Share 1.56
EPS $6.00
ROA 15.14%
ROE N/A
Debt/Equity 2.53
Net debt/EBITDA N/A
Current ratio 3.68
Quick ratio 2.80